Halozyme Therapeutics, Inc. (HALO)
-NasdaqGS 7.53 
0.04(0.53%) 3:07PM EDT - Nasdaq Real Time Price
| Prev Close: | 7.57 |
|---|
| Open: | 7.73 |
|---|
| Bid: | 7.54 x 600 |
|---|
| Ask: | 7.55 x 1100 |
|---|
| 1y Target Est: | 7.79 |
|---|
| Beta: | 1.45 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 7.42 - 7.92 |
|---|
| 52wk Range: | 3.86 - 9.92 |
|---|
| Volume: | 1,174,073 |
|---|
| Avg Vol (3m): | 1,351,200 |
|---|
| Market Cap: | 846.49M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.51 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- American Society Of Clinical Oncology Abstracts Point To Potential Profitsat Seeking Alpha(Tue 10:11AM EDT)
- Baxter Receives Marketing Authorization for HyQvia in European UnionBusiness Wire(Tue 9:00AM EDT)
- 3 Humongous Health-Care Stocks This Weekat Motley Fool(Sat, May 18)
- HALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhEDGAR Online(Fri, May 17)
- Cancer Drug Drama Rocks 2 Biotech Stocksat Motley Fool(Thu, May 16)
- Halozyme rises on pancreatic cancer drug studyAP(Thu, May 16)
- Halozyme rises on prostate cancer drug studyAP(Thu, May 16)
- Little-noticed firm makes a splash with pancreatic cancer treatmentat MarketWatch(Thu, May 16)
- [video] Biotech's Next Big Thing -- ASCO IIat TheStreet(Thu, May 16)
- Why Halozyme Therapeutics Shares Soaredat Motley Fool(Thu, May 16)
- Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual MeetingPR Newswire(Wed, May 15)
- 10 ASCO '13 Abstracts You Can Read Right Nowat TheStreet(Wed, May 15)
- HALOZYME THERAPEUTICS INC FinancialsEDGAR Online Financials(Wed, May 15)
- Halozyme Therapeutics Management Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)at Seeking Alpha(Wed, May 15)
- Short Interest Increases 11.2% For HALOat TheStreet(Fri, May 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 18.22 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.57 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.14 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery ...
View More